Treatment of Skin and Soft Tissue Infections

07/11/23 • 27 min

In this episode, Kyle Molina, PharmD, BCIDP, provides an overview of treatment of skin and soft tissue infections (SSTIs) and challenges in practice. Listen as he gives perspectives on:

Guideline recommendations for treatment of purulent and nonpurulent SSTIs
Logistical challenges with IV and oral antibiotics
Pros and cons of various locations of care
Data supporting the safety and efficacy of long-acting lipoglycopeptides for treatment of SSTIs
Use of long-acting lipoglycopeptides in special populations of interest, including patients with obesity, diabetes, and injection drug use
Overall place in therapy of long-acting lipoglycopeptides for SSTIs

Faculty:

Kyle Molina, PharmD, BCIDP
Infectious Diseases Clinical Pharmacist
Scripps Green Hospital
La Jolla, California
Link to full program:

CCO: https://bit.ly/3J4mg8h
ProCE: https://bit.ly/3P0vB4E

In this episode, Kyle Molina, PharmD, BCIDP, provides an overview of treatment of skin and soft tissue infections (SSTIs) and challenges in practice. Listen as he gives perspectives on:

Guideline recommendations for treatment of purulent and nonpurulent SSTIs
Logistical challenges with IV and oral antibiotics
Pros and cons of various locations of care
Data supporting the safety and efficacy of long-acting lipoglycopeptides for treatment of SSTIs
Use of long-acting lipoglycopeptides in special populations of interest, including patients with obesity, diabetes, and injection drug use
Overall place in therapy of long-acting lipoglycopeptides for SSTIs

Faculty:

Kyle Molina, PharmD, BCIDP
Infectious Diseases Clinical Pharmacist
Scripps Green Hospital
La Jolla, California
Link to full program:

CCO: https://bit.ly/3J4mg8h
ProCE: https://bit.ly/3P0vB4E

Previous Episode

Answering the Questions on Which HIV PrEP for Which Patient: Latesha Elopre and Jason Farley

In this episode, Latesha Elopre, MD, MSPH, and Jason Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN, answer questions about HIV PrEP including:

How long someone can receive PrEP and the monitoring that is needed over time
Recommendations for monitoring bone health while receiving oral PrEP
Treatment as prevention and PrEP efficacy data and options for people who inject drugs
The role of circumcision in HIV prevention
The use of PrEP in pregnancy
Concern for ART resistance if someone seroconverts while receiving PrEP, especially when using nondaily PrEP options
The possibility of using FTC/TAF on demand
Inequities in adherence and persistence
Cost considerations with different PrEP modalities
Recommendations for hospitalized patients receiving PrEP
PrEP considerations for patients with renal dysfunction and higher BMIs
PrEP efficacy based on site of exposure

Presenters:

Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
Assistant Dean of Diversity and Inclusion
General Medical Education
University of Alabama at Birmingham
Birmingham, Alabama

Jason Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN
Professor
School of Nursing
Johns Hopkins University
Nurse Practitioner
Department of Infectious Diseases
John G. Bartlett Specialty Practice
Baltimore, Maryland

Link to full program:
https://bit.ly/3Fqdgs9

Next Episode

Viral Hepatitis Update: CCO Independent Conference Coverage of EASL 2023

In this episode, Stefan Zeuzem, MD, discusses new data on viral hepatitis presented at EASL 2023, including:

Hepatitis B virus
- Durability of response with bepirovirsen
- HBsAg loss with siRNA VIR-2218 combined with either VIR-3434 (novel monoclonal antibody) or pegIFN-alfa
Hepatitis delta virus
- 96-week follow-up of immediate vs delayed bulevirtide
- Off-treatment response for lonafarnib + ritonavir ± pegIFN-alfa
- Safety and efficacy outcomes with siRNA JNJ-3989 + nucleos(t)ide analogue
Hepatitis C virus
- Collaborative service at opiate substitution treatment clinic to improve linkage to care in Ireland
- Nurse-led test-and-treat program to increase screening and diagnosis at female prisons in the United Kingdom
- FIND-C study using machine learning to improve screening-to-diagnosis ratio using clinical factors and social determinants of health

Presenter:

Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine
JW Goethe University Hospital
Frankfurt, Germany

Link to full program:

https://bit.ly/3JQQj3J